Biogen News and Research

RSS

Experimental therapy dramatically reduces seizures in children with Dravet syndrome

A new experimental treatment for children with a hard-to-treat form of epilepsy is safe and can reduce seizures dramatically, helping them lead much healthier and happier lives, the findings of a UCL and Great Ormond Street Hospital-led international clinical trial show.

4 Mar 2026

New Mandarin cognitive tests improve dementia diagnosis for Chinese older adults

Asian Americans are the fastest-growing group of older adults in the U.S., but they often face language and cultural barriers when seeking care for dementia-related symptoms.

26 Feb 2026

Single blood test predicts onset of Alzheimer’s symptoms years ahead

Researchers at Washington University School of Medicine in St. Louis have developed a method to predict when someone is likely to develop symptoms of Alzheimer's disease using a single blood test.

19 Feb 2026

Global Alzheimer’s Platform Foundation announces strategic collaboration and partnership with Spear Bio for the transformative Bio-Hermes-002 study

The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study.

From Spear Bio 18 Jan 2026

Study elucidates how anti-amyloid antibody therapy lecanemab works in Alzheimer's disease

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline.

25 Nov 2025

Analysis highlights the differing physical side effects of antidepressants

Antidepressants can differ widely in how they physically affect the body, including around a 4 kg difference in weight change between certain drugs (approximately 2.5 kg weight loss from agomelatine and 2kg weight gain from maprotiline), confirms a systematic review and meta-analysis published in The Lancet.

22 Oct 2025

Genetic inflammatory signature defines depression subtypes and treatment response

Researchers led by Prof. Alessandro Serretti at Kore University of Enna have identified a genetic inflammatory signature that defines specific depression subtypes and influences how patients respond to antidepressant medications, according to new peer-reviewed research published today in Genomic Psychiatry.

21 Oct 2025

New study offers hope for patients with treatment-resistant focal epilepsy

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly to available therapies.

21 Oct 2025

Largest study of African American brain tissue reveals key Alzheimer gene activity

The prevalence of Alzheimer disease (AD) is approximately two times higher in African Americans (AA) compared to White/European-ancestry (EA) individuals living in the U.S.

8 Oct 2025

Menopause not linked to increased risk of disability in women with multiple sclerosis

The largest study of its kind has found menopause is not associated with an increased risk of disability in women with multiple sclerosis (MS).

29 Sep 2025

Early warning signs of MS appear years before diagnosis and affect all communities in similar ways

A major UK study has revealed that the early warning signs of multiple sclerosis (MS) - including pain, mood changes, and neurological symptoms such as numbness and tingling – may appear years before diagnosis and affect all communities in similar ways.

24 Sep 2025

Ocrelizumab provides superior control of multiple sclerosis relapses compared to other therapies

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses compared with fingolimod, natalizumab, and alemtuzumab.

23 Sep 2025

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

Mentavi Health announced that its landmark, real-world validation study of the Mentavi Diagnostic Evaluation has been published in the peer-reviewed Journal of Clinical Psychiatry (JCP), a widely read and respected journal.

12 Sep 2025

Under Trump, FDA seeks to abandon expert reviews of new drugs

FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency's decisions from public scrutiny.

12 Sep 2025

CRISPR-based therapeutic approach designed to treat fatal pediatric disease

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare condition associated with stroke, aortic dissection (tearing) and death in childhood.

11 Sep 2025

'Resistin like molecule gamma' punches holes into heart cells after myocardial infarction

Nina Kumowski, MD, of the Department of Radiology and Center for Systems Biology at Massachusetts General Hospital, is the lead author and Matthias Nahrendorf, MD, PhD of the Department of Radiology and Center for Systems Biology at MGH, is the senior author of a paper published in Science, "Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardia."

9 Sep 2025

Blood-based biomarkers reveal barriers to diversity in Alzheimer’s disease trials

Some of the populations with the highest risk for Alzheimer's disease remain greatly underrepresented in clinical trials-and a new study helps explain why.

5 Sep 2025

Most US neurologists prescribing multiple sclerosis drugs receive pharma industry payments

Nearly 80% of US neurologists prescribing drugs for multiple sclerosis (MS) received at least one pharma industry payment, with higher volume prescribers more likely to be beneficiaries, finds a 5 year analysis of Medicare database payments, published in the open access journal BMJ Open.

27 Aug 2025

New study reveals long road to seizure control for people with focal epilepsy

Antiseizure medications help the majority of people with focal epilepsy, a common form of the neurological disorder.

25 Aug 2025

Modest gift card boosts enrollment of low-income participants in Alzheimer’s registry

Offering a modest gift card significantly increased enrollment of low-income individuals in a patient registry designed to accelerate Alzheimer's disease clinical trials, a new USC study finds.

22 Aug 2025